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Abstract
Background: In people, bile acid diarrhoea is a prevalent complication of Crohn’s disease and diarrhoea-
associated irritable bowel syndrome. Affected patients typically respond to bile acid sequestrants, such as
cholestyramine, but human gastroenterologists often fail to recognize bile acid diarrhoea. Consequently, bile
acid diarrhoea is regarded as an underrecognized and undertreated condition in human medicine. Due to
lack of diagnostic tools, clinical response to bile acid sequestrants is often used to confirm a diagnosis of bile
acid diarrhoea in people.
Several recent studies have shown that bile acid dysmetabolism also occurs in dogs with chronic
enteropathies. It has further been shown that dogs with chronic enteropathies have significantly decreased
expression of a bile acid transport protein in the ileum compared to healthy dogs, which correlates with
faecal bile acid dysmetabolism. Consequently, in spite of the lack of reports in the literature, bile acid
diarrhoea is likely to exist in dogs as well.
Case descriptions: Two dogs, an 8-year old Rottweiler and a 4.5-year old Siberian Husky were evaluated for
chronic watery diarrhoea. Neither dog responded to dietary trials, probiotics, cyclosporine, faecal microbial
transplantations or metronidazole. One of the dogs responded to high daily doses of corticosteroids, which
were however associated with unacceptable side effects. The other dog was refractory to all standard
treatment protocols, including cyclosporine and corticosteroids. Since none of the dogs responded
satisfactorily to standard treatment or modulation of the intestinal microbiome, a suspicion of possible bile
acid diarrhoea was raised. Treatment with cholestyramine, a bile acid sequestrant was initiated and resulted in
marked improvement of faecal consistency, frequency of defecation and activity level in both dogs.
Conclusion: This report presents two dogs with presumed bile acid diarrhoea that were successfully treated
with cholestyramine. Therefore, bile acid diarrhoea should be considered as a possible diagnosis in dogs with
treatment-refractory chronic diarrhoea.
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Plain English summary
Bile acids are produced by the liver and excreted in the
small intestine where they are required for proper diges-
tion of fat. They get absorbed in the last segment of the
small intestine. In people with Crohn’s disease or irrit-
able bowel syndrome associated with diarrhoea, absorp-
tion mechanisms fail, and excessive amounts of bile
acids reach the large intestine where they can cause what
is known as bile acid diarrhoea (BAD). Cholestyramine,
a drug that binds bile acids, is used for treatment of
BAD in people. Recent research has shown that dogs
with chronic small intestinal inflammation may also have
difficulty absorbing bile acids and end up with excessive
concentrations in the large intestine. We describe two
dogs with chronic diarrhoea that responded well to cho-
lestyramine treatment when all other treatments had
failed. We believe that BAD should be considered as a
diagnosis in dogs with chronic small intestinal inflam-
mation and diarrhoea that are refractory to standard
treatment, and that cholestyramine treatment may be
useful in these situations.
Background
Primary bile acids (BAs) are synthesized in the liver and
secreted into the small intestine, where they participate
in fat absorption. Approximately 95% of BAs are reab-
sorbed in the ileum and undergo enterohepatic circula-
tion [1]. This process is mediated by the apical sodium-
dependent BA transporter (ASBT). Unabsorbed BAs are
transformed by 7α-dehydroxylating colonic bacteria (e.g.,
Clostridium hiranonis in dogs) to secondary BAs [2]. In
people, various chronic gastrointestinal disorders are as-
sociated with increased amounts of BAs in the colon.
This stimulates electrolyte and water secretion and in-
creases mucosal permeability and colonic motility [3].
Bile acid dysmetabolism and BA diarrhoea (BAD) have
been reported in 40% of patients with Crohn’s disease
and 32% of patients with diarrhoea-predominant irrit-
able bowel syndrome (IBS-D) [4]. Patients with BAD
typically respond to BA sequestrants (e.g., cholestyr-
amine). However, despite a high prevalence, BAD is con-
sidered an underdiagnosed and undertreated condition
in gastroenterology [5].
Bile acid dysmetabolism has recently been reported in
several studies in dogs with chronic enteropathy (CE)
[6–9]. Furthermore, decreased expression of the ASBT
in the ileum of dogs with CE has been documented [7].
However, the authors could not find any published re-
ports describing the clinical course and treatment of
BAD in dogs. Therefore, the aim of this report was to
describe the clinical presentation and response to chole-




An 8-year old neutered male Rottweiler with a body
weight (BW) of 52 kg and a body condition score (BCS)
of 5/9 was presented for a severe flare-up of watery diar-
rhoea and anorexia. The dog was already under treat-
ment as an outpatient for previously diagnosed CE at a
referral animal hospital, and was now admitted for fluid
therapy and supportive care at the same animal hospital.
On admission, the dog was on maintenance treatment
with budesonide (3 mg on 2 days out of 3, Entocort; Til-
lotts Pharma GmbH, Rheinfelden, Germany) and a sin-
gle protein source diet. The dog had been clinically
stable with normal faeces for 2.5 years. Diarrhoea ap-
peared once when budesonide had been tapered to 3 mg
every other day, but was absent on a maintenance dose
of 3 mg budesonide 2 days out of 3. Biopsies from the
gastrointestinal tract had been collected endoscopically
4 years previously and showed mild to moderate
lymphocytic-plasmacytic inflammation. Laboratory and
imaging data at the time of admission to the animal hos-
pital are shown in Tables 1 and 2.
Prednisolone (Prednisolon; Pfizer, Sollentuna, Sweden)
at a dose of 10 mg q 24 h was added to the maintenance
dose of budesonide for 3 weeks, which brought the diar-
rhoea temporarily into remission but led to calcinosis
cutis, prompting cessation of prednisolone treatment
and tapering of budesonide to 3 mg q 48 h. This was as-
sociated with recurrence of diarrhoea. The dog contin-
ued to have diarrhoea as well as excessive flatulence and
halitosis during the following 12months. Numerous
treatment protocols, including additional immunosup-
pressive treatments such as cyclosporine and mycophe-
nolate mofetil, metronidazole and dietary changes were
tried at different times during this period (Table 3). A
faecal microbiota transplantation was given once as a
rectal enema at a dose of 5 g of frozen donor stool per
kg body weight as described by Chaitman and co-
workers [10]. The stool was thawed and blended with
0.9% saline on the day of administration. The donor dog
was clinically healthy, free of intestinal parasites, bacter-
ial pathogens and extended beta-lactamase resistant
E.coli.
The dog was refractory to all treatments and had li-
quid diarrhoea 4–5 times daily, including once at night,
and a canine inflammatory bowel disease activity (CIB-
DAI) index of 7 (consistent with moderate IBD) [11].
The poor response to medical and dietary intervention
raised the suspicion of BAD. Cholestyramine (Kolestyra-
min Alternova; Orifarm Generics, Odense, Denmark)
treatment was started with 2 g q 24 h for a week. The
owners immediately noticed that the faeces became
much firmer during 12 h after cholestyramine adminis-
tration, but watery diarrhoea reappeared later during the
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day. The dose was increased to 2 g q 12 h, which further
improved the quality of the faeces, reduced the fre-
quency of defecation to 2–3 times daily, and markedly
reduced flatulence. After increasing the dose to 3 g q 12
h, the diarrhoea stopped, CIBDAI had decreased to 2
(clinically insignificant disease) and faecal scores had im-
proved from 5/5 (liquid diarrhoea) to 3/5 (formed but
soft faeces) [12]. Dose reduction to 2 g cholestyramine q
12 h led to return of unformed feces within 36 h. The
cholestyramine dose was again successfully increased to
3 g q 12 h. At the time of writing, diarrhoea had not re-
curred for 11 months, excessive flatulence had disap-
peared, and vomiting had ceased. Furthermore, the BCS
had increased to 7/9 and the dog owner described the
dog as more playful than during the past several years.
Case 2
A 4.5-year old male neutered Siberian Husky with a BW
of 34 kg and a BCS of 6.5/9 was referred for FMT. The
dog had a life-long history of partially food-responsive
chronic diarrhoea that had been somewhat stable as long
as the dog only ate a hydrolyzed soy protein diet (Purina
HA) with a probiotic supplement (Purina Fortiflora).
Even when keeping a strict diet and using the probiotic
supplement, flare-ups of diarrhoea and hyporexia oc-
curred every week and lasted for 1–3 days. Several other
diets had been tried previously, all resulting in diarrhoea
(Table 3). The condition had deteriorated during the last
4 months to persistent diarrhoea, lethargy, marked
hyporexia and 15% loss of BW. The dog defecated up to
7 times daily with a faecal score of 3–5/5 and had a CIB-
DAI score of 13 (severe IBD) [12]. For financial reasons,
endoscopy had never been performed. Co-morbidities
included zinc-responsive dermatosis and chronic bleph-
aritis. Treatment with elemental zinc improved the skin
condition partially. Neither cyclosporine treatment for
3.5 months, nor prednisolone improved the gastrointes-
tinal signs. Metronidazole had been prescribed several
times, without improvement of faecal quality. Laboratory
and imaging data at the time of referral are shown in Ta-
bles 1 and 2. On physical examination, the dog was quiet
with marked blepharitis, periorbital dermatitis and
Table 1 Selected serum biochemistry, haematology and faecal analysis
Parameter Reference interval Case 1 Case 2
Total leukocyte count 6.2–11.4 × 109/L 10.8a 8.03a
Haematocrit 37.3–61.9% 44.9 62.7
Total protein 60–75 g/L 62 55
Albumin 29–39 g/L 34 32
Cholesterol 4.1–7.3 mmol/L 7.1 4.9
Alanine aminotransferase 0.3–1.3 ukat/L 0.8 0.7
Alkaline phosphatase 0.1–1.7 ukat/L 54 1.8
Creatinine 65–105 μmol/l 69 101
Blood urea nitrogen 3.8–9.0 mmol/L 2.9 6.7
C-reactive protein 0–30 mg/L 45 < 10
Cobalamin 180–700 pmol/l 468 405
Folate 15–45 nmol/l > 54 16
Specific canine pancreatic lipase 0–200 μg/L 67 51
Trypsin-like immunoreactivity 5.5–35 μg/L 22 18
Faecal tests
Faecal sedimentation-flotation Negative Negative Negative
IDEXX SNAP Giardia test Negative Negative Negative
Dysbiosis index < 2 −0.7 N/A
Clostridium hiranonis 5.1–7.1 Log DNA/g 5.1 N/A
Bold numbers – results outside reference interval. aNormal white blood cell differential count, N/A not applicable
Table 2 Gastrointestinal ultrasound report
Case
1
Duodenum: mildly thickened muscularis layer, mildly increased wall thickness. Jejunum: mild amount of mucosal speckles present in the oral
part, mildly thickened muscularis layer in the aboral part. Mesenterial lymph nodes: mild enlargement, otherwise normal appearance. The
remaining gastrointestinal tract within normal limits
Case
2
Jejunum: prominent muscularis layer in some areas.
The remaining gastrointestinal tract within normal limits
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moderate facial crusting of the mucocutaneous junc-
tions. The abdomen was moderately tense and painful
on palpation. Liquid faeces were detected upon rectal
palpation. FMT was given as a rectal enema, using the
same donor and protocol as previously described, which
initially was associated with a remarkable improvement
regarding faecal quality, appetite, activity level and peri-
orbital dermatitis [10]. However, ten days later, the dog
appeared to have abdominal pain and diarrhoea
returned, followed by pica, hyporexia and lethargy. Four
days later, the dog came back for a second FMT. The
same donor and protocol were used for the procedure,
but no improvement of the gastrointestinal signs was
noted. Budesonide treatment, 3 mg q 24 h, was initiated
but led to more severe diarrhoea and was stopped after a
few days. Loperamide was then prescribed without any
improvement. A third FMT was performed 14 days later,
without clinical improvement. At this time, cholestyr-
amine at 2 g q 24 h was prescribed. Faecal quality and
activity level improved during the first 12 h after each
cholestyramine dose, but deteriorated during the follow-
ing 12 h until the next dose. The cholestyramine dose
was increased to 2 g q 12 h, which led to resolution of
diarrhoea, decreased frequency of defecation, improved
appetite and a more active and playful behaviour. Five
months later at follow-up, twice daily cholestyramine
treatment was still effective against diarrhoea, hyporexia
and lethargy, and the CIBDAI score had decreased to 3
(clinically insignificant disease). Although occasional
flare-ups of hyporexia and diarrhoea still occurred, these
episodes were much shorter and occurred less frequently
than before. Furthermore, the flare-ups of zinc-
responsive dermatosis and chronic blepharitis occurred
significantly less frequently than before.
Discussion
This report describes successful treatment of chronic re-
fractory diarrhoea with a BA sequestrant in two dogs.
Recent studies have reported faecal BA dysmetabolism
and decreased expression of ASBT in the ileum of dogs
with CE [6–9]. Dogs with CE had significantly lower
amount of total secondary BAs, and increased percent-
age of primary BAs compared to healthy dogs [7–9].
Similar BA dysmetabolism has been shown in people
with inflammatory bowel disease too [13]. In another re-
cent study, the serum concentration of 7α-hydroxy-4-
Table 3 Medical and dietary interventions besides corticosteroids prior to cholestyramine treatment
Immunosuppressanta Case 1 Case 2
Cyclosporine (Cyclance vet; Virbac, Kolding, Denmark) 5 mg/kg q 24 h N/A
Cyclosporine (Modulis Vet; Ceva, Lund, Sweden) N/A 5mg/kg q 24 h
Mycophenolate (Myfenax; Teva, Haarlem, the Netherlands) 10 mg/kg q 12 h N/A
Antibiotics
Metronidazole (Flagyl; Sanofi, Stockholm, Sweden) 10mg/kg q 24 h 15 mg/kg q 24 h
Miscellaneous drugs
Loperamide (Imodium; McNeil, Solna, Sweden) 0.08 mg/kg q 12 h 0.1 mg/kg q 12 h
Olsalazine (Dipentum; Pharmanovia, Basildon, Great Britain) 10 mg/kg q 12 h 15 mg/kg q 12 h
Pro-and prebiotics
Mixed pre- and probiotic (Pro-fibre; Protexin vet) 15 g q 12 h 15 g q 12 h
Single strain probiotic (Fortiflora; Purina) N/A 1 sachet q 24 h
Multistrain probiotic (Sivomixx; Ormendes) 1 sachet q 24 h 1 sachet q 24 h
Psyllium (Vi-Siblin; Meda) 30 ml q 12 h N/A
Diets
KD hydrolyzed protein diet (RC Hypoallergenic soy and rice) Y Y
KD hydrolyzed protein diet (Purina HA soy and corn) Y Y
KD hydrolyzed protein diet (Hill’s Z/D chicken and rice) N/A Y
KD hydrolyzed protein diet (Specific CDD-HY salmon and rice) N/A Y
KD single protein (RC Sensitivity control duck and tapioca) Y N/A
KD single protein (Hill’s D/D salmon and rice) Y N/A
KD fibre rich (Hill’s Gastrointestinal Biome Digestive) Y N/A
Faecal Microbial Transplantation as rectal enema
Treatments 1 3
aadd-on immunosupressants were given one at a time, N/A not applicable, KD kibble diet, Y dietary trial performed, RC Royal Canin
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cholesten-3-one (C4), a serum biomarkers of hepatic BA
synthesis, was compared between healthy dogs and dogs
with chronic diarrhoea [14]. Three of 17 dogs with
chronic diarrhoea had serum C4 concentrations signifi-
cantly above the calculated upper limit of the reference
interval. These dogs were all partly or fully refractory to
conventional therapy. Based on these previous studies it
is likely that bile acid diarrhoea is a disease entity in
dogs too, but reports on the clinical course and treat-
ment of BAD in dogs are lacking.
It is estimated that 5–27% of dogs with CE have non-
responsive enteropathy (NRE), if studies including only
dogs with protein-losing enteropathy are excluded [15–
23]. If dogs with food responsive enteropathy were ex-
cluded, the odds ratio (OR) of becoming refractory to
treatment was significantly higher in steroid-responsive
dogs compared to food-responsive dogs [16]. Potentially,
some dogs with NRE may have BAD.
Bile acid diarrhoea is prevalent in humans with
Crohn’s disease and IBS-D. Recent recommendations
state that BAD should be considered early in patients
with chronic diarrhoea [24]. Still, BAD remains an
underrecognized and undertreated condition [5, 24].
There are several pathogenetic mechanisms described
that lead to BAD in humans with gastrointestinal disor-
ders, the most common of which is malabsorption of
BAs in patients with ileal disease, and dysbiosis, which is
associated with a decreased ability to convert primary
BAs to secondary BAs. Clostridium hiranonis is a bacter-
ial species that plays a prominent role in converting pri-
mary BAs to secondary BAs [2]. Decreased abundance of
C. hiranonis has been reported in dogs with CE [9, 25].
However, one of the dogs in this report had a normal
dysbiosis index and faecal C. hiranonis abundance, leav-
ing malabsorption the most likely reason for BAD.
Treatment with glucocorticoids in rodent models and
healthy human volunteers is associated with increased
expression of ASBT, which likely increases BA reabsorp-
tive capacity in the ileum [26, 27]. This positive effect on
BA transport might have affected one of the case dogs as
well, since diarrhoea ceased with higher doses of cortico-
steroids. However, this may also have been due to the
anti-inflammatory and immune-suppressive properties
of corticosteroids.
Cholestyramine is a sequestrant with a high affinity for
BAs. When binding to BAs, an insoluble complex is
formed that is excreted in the feces. Cholestyramine is
recommended for use in dogs at an oral dose of 0.5–2.0
g/dog q 12 h for reduction of idiopathic hypercholester-
olaemia [28]. Furthermore, cholestyramine has success-
fully been used to treat cyanobacterial toxicosis in a dog
at a dose of 172 mg/kg for 17 days [29]. Several drugs
and toxins must be bound to BAs to undergo entero-
hepatic circulation. Therefore, the irreversible binding of
BAs to cholestyramine inhibits systemic toxin absorption
and increases faecal excretion. In healthy laboratory Bea-
gle dogs, the elimination rate of the non-steroidal anti-
inflammatory drug (NSAID) tenoxicam was drastically
accelerated when multiple doses of oral cholestyramine
were given following tenoxicam injection, in contrast to
both placebo and charcoal administration [30]. In
Plumb’s Veterinary Drugs, cholestyramine is recom-
mended to treat cyanotoxin exposure, NSAID toxicosis
and vincristine overdose [31].
One recent study reported that a cholestyramine dose
of 0.7 mg/kg q 24 h administered for 14 days to 12
healthy Beagle dogs appeared to be clinically safe [32].
No side effects or weight loss were noted. The faecal dry
matter content increased with cholestyramine treatment,
but the number of bowel movements did not increase
and faecal scores were still in the normal range. Macro-
nutrient apparent total tract digestibility decreased after
cholestyramine treatment, but remained in the normal
range. It should be noted that the dose used in these
studies was 7 times higher than the doses used in this
case report (0.058 mg/kg q 12 h and 0.059 mg/kg q 12 h,
respectively). However, the long term consequences of
cholestyramine treatment in dogs need to be studied.
In people, first-line treatment of BAD is cholestyramine,
but gastrointestinal side effects, such as constipation,
bloating, nausea, flatulence, abdominal pain and worsen-
ing diarrhoea are common [24]. This could affect compli-
ance and make it difficult to titrate dosages to clinical
effect. Side effects were less prominent and compliance
was better when using newer and more expensive BA
sequestrants such as colesevelam or colestipol. Besides
gastrointestinal side effects, an over 3-fold increase in ala-
nine aminotransferase (ALT) was noted in 11/67 healthy
volunteers [33]. This increase was considered benign, and
was not documented in any of the case dogs at follow-up
visits. A few cases of vitamin K malabsorption and spon-
taneous bleeding have been reported in people treated
long term with cholestyramine [34–37]. No negative effect
on vitamin K absorption was noted in healthy laboratory
Beagle dogs treated with dicumarol and Vitamin K when
cholestyramine was given at a dose of 200mg/kg q 24 h
[38]. When the cholestyramine dose was increased to 1.0
g/kg, vitamin K absorption was somewhat delayed, but
normalized within 24 h. A massive dose of 3.0 g/kg q 24 h
of cholestyramine was associated with decreased absorp-
tion of vitamin K if the vitamin and cholestyramine was
given at the same time, but not if cholestyramine was
given 17 h prior to vitamin K.
In people, 3 categories of tests are available to confirm
the diagnosis of BAD [39]. The SeHCAT test measures
loss of fecal BAs and is considered the gold standard
test, but is only available in very few laboratories world-
wide [4]. Alternately, serum levels of of bile acid
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synthesis, including 7α-hydroxy-4-cholesten-3-one (C4)
or the ileal regulatory hormone, fibroblast growth factor
19 (FGF19), can be measured by high-performance li-
quid chromatography (HPLC). These tests have good
specificity and negative predictive value for BA malab-
sorption in patients with IBS-D or functional diarrhoea,
but a lower sensitivity for other types of BA malabsorp-
tion. The C4 test is regarded as a good screening test to
rule out BA malabsorption, but both C4 and FGF 19
have diurnal variation, which can cause false positive re-
sults [3, 40]. Measurement of faecal BAs can be per-
formed using HPLC, but requires a 48 h stool collection
period, which is not popular among patients [39]. These
diagnostic tests are not widely available. Hence, clinical
response to cholestyramine is often used to diagnose
BAD in people [3]. This approach can be problematic, as
a failed empiric trial with cholestyramine, often due to
side effects, does not exclude BAD as a diagnosis [40].
However, the lack of tests to diagnose BAD should not
exclude patients with chronic diarrhoea from empiric
treatment.
In dogs, analysis of faecal BAs has been described, but
a reference interval from a larger population of healthy
dogs is lacking [6–9]. Until tools to diagnose BAD in
veterinary medicine are validated and available, we
hypothesize that, as in people, empirical treatment with
BA sequestrants can be tried in dogs with chronic re-
fractory diarrhoea. This treatment saved the two case
dogs from euthanasia.
Conclusion
This case report describes successful treatment of two
dogs with chronic, long-lasting refractory diarrhoea with
cholestyramine. Clinical response to cholestyramine is
often used to diagnose BAD in people. Based on re-
sponse to treatment of the two dogs in this study, we
presume that the dogs in this report had BAD. Chole-
styramine might serve as an alternative treatment option
for dogs with intractable diarrhoea that do not respond
to standard treatment protocols.
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